News

Novo Nordisk: The Market Hasn't Given It Enough Respect

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Ozempic is better than approved therapies at slashing risk of disease affecting 7M Americans

GLP-1s - which mimic the effects of the hormone that stimulates insulin release, suppressing glucagon, and slowing gastric ...